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Background: Delafloxacin is an investigational anionic fluoroquinolone in development for oral or intravenous
administration for the treatment of infections caused by Gram-positive (including MRSA), Gram-negative, atyp-
ical and anaerobic organisms.
Objectives: To establish the non-inferiority of delafloxacin compared with vancomycin plus aztreonam for the
treatment of acute bacterial skin and skin structure infections and to compare the safety of the two
antimicrobials.
Patients and methods: A Phase 3, multicentre, randomized, double-blind, active-controlled study with 660 pa-
tients compared delafloxacin 300 mg or vancomycin 15 mg/kg plus aztreonam 2 g each administered twice daily
intravenously for 5–14 days. Non-inferiority was evaluated by objective response (20% erythema reduction) at
48–72 h after initiation of study drug, investigator subjective assessment of outcome and microbiological re-
sponses. Clinical Trials Registration: NCT01811732. EudraCT number: 2012-001767-71.
Results: In the ITT analysis set, the objective response was 78.2% in the delafloxacin arm and 80.9% in the
vancomycin/aztreonam arm (mean treatment difference, #2.6%; 95% CI, #8.78% to 3.57%). Investigator-
assessed cure was similar between the two groups at follow-up (52.0% versus 50.5%) and late follow-up (70.4%
versus 66.6%). Bacterial eradication of MRSA was 100% and 98.5% in the delafloxacin group and the vanco-
mycin/aztreonam group, respectively. Frequency of treatment-emergent adverse events in the delafloxacin and
vancomycin/aztreonam groups was similar. Treatment-emergent adverse events leading to study drug discon-
tinuation were higher in the vancomycin/aztreonam group compared with the delafloxacin group (4.3% versus
0.9%).
Conclusions: Delafloxacin, an anionic fluoroquinolone, was statistically non-inferior to vancomycin/aztreonam
at 48–72 h following the start of therapy and was well tolerated as monotherapy in the treatment of acute bac-
terial skin and skin structure infections.
Introduction
Acute bacterial skin and skin structure infections (ABSSSIs) have di-
verse aetiologies due, in part, to varying epidemiological settings,
with many different microbes identified as potential causes.1,2
MRSA and other MDR Gram-positive and Gram-negative bacteria
are of particular concern due to significant patient morbidity
coupled with high utilization of healthcare resources and costs.3–6
Many antimicrobials are generally effective for ABSSSIs, although
their use is limited by resistance7,8 and adverse effects.9 These
challenges have stimulated efforts to develop new antimicrobial
agents with a favourable safety profile and clinical efficacy with
appropriate pathogen coverage aligning with antimicrobial stew-
ardship principles.5
Delafloxacin is an anionic fluoroquinolone for oral or intraven-
ous administration recently approved by the FDA for the treatment
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of ABSSSI, caused by designated susceptible bacteria including
Gram-positive organisms (including MRSA) and Gram-negative or-
ganisms. Delafloxacin is chemically distinct from other quinolones
in its size, shape and charge profile. These properties result in a
highly active agent, particularly against Gram-positive patho-
gens.10,11 Delafloxacin is more active in vitro than levofloxacin
against most Gram-positive pathogens, including levofloxacin
non-susceptible isolates, and is 32-fold more active than levo-
floxacin against MRSA isolates.12 The spectrum of activity13–15 of
delafloxacin suggests a potential for use in infections with Gram-
positive and Gram-negative pathogens and mixed pathogens.
Previous Phase 216,17 ABSSSI studies demonstrated that dela-
floxacin is well tolerated and has favourable clinical efficacy com-
pared with tigecycline,16 linezolid and vancomycin.17 Statistically
better outcomes in obese patients with delafloxacin compared
with vancomycin in one Phase 2 study led to pre-specified second-
ary endpoints in obese patients in the study reported here.17
The primary objective of this study was to evaluate the clinical
efficacy and safety of delafloxacin monotherapy compared with
vancomycin plus aztreonam for the treatment of ABSSSIs at
48–72 h following treatment initiation in accordance with FDA18




This Phase 3, multicentre, multinational, stratified, randomized, double-
blind trial assessed the efficacy and safety of intravenous delafloxacin com-
pared with vancomycin/aztreonam for the treatment of adults with
ABSSSIs. Clinical Trials Registration: NCT01811732. EudraCT number: 2012-
001767-71.
Ethics
This study was conducted in compliance with the principles of ICH E6(R1)
and the principles of the World Medical Association Declaration of Helsinki.
A written informed consent in compliance with US Title 21 Code of Federal
Regulations Part 50, ICH E6(R1) and other applicable regulatory require-
ments was obtained from each patient or legally authorized representative
before entering the study or performing any unusual or non-routine pro-
cedure that involved risk to the patient. A list of institutional review boards
used for this study is available.
Patients
Eligibility criteria were age18 years and a diagnosis of ABSSSI classified as
cellulitis/erysipelas, wound infection, major cutaneous abscess or burn in-
fection with 75 cm2 of erythema and 2 signs of systemic infection.
Exclusion criteria were consistent with current guidance and included re-
ceipt of systemic antibiotic therapy in the 14 days before enrolment unless
one of the following was documented: the patient received at least 48 h of
antibiotic therapy for ABSSSI and clinical progression of ABSSSI was docu-
mented; the patient completed a treatment course within 7 days for an in-
fection other than ABSSSI with an antibacterial drug not having activity
against bacterial pathogens that cause ABSSSI; and patients who received
one dose of a single, potentially effective, short-acting antimicrobial drug
for the treatment of the ABSSSI under study in the 14 days before study
entry. Prior single dose antibiotic use was limited to no more than 25% of
the total randomly assigned patients. Further details regarding the
eligibility and exclusion criteria are available in Table S1 (available as
Supplementary data at JAC Online).
Patients were enrolled at 34 study centres in seven countries between
April 2013 and June 2014 and randomized (1:1) to delafloxacin or vanco-
mycin/aztreonam using an interactive web response system. Vancomycin
was chosen as the comparator in accordance with FDA and EMA guide-
lines.18,19 Randomization was stratified by infection type, ensuring that25%
and 35% of patients had a major cutaneous abscess or wound infection,
respectively.
Interventions
Patients received intravenous delafloxacin 300 mg or vancomycin
15 mg/kg (actual body weight) plus aztreonam 2 g every 12 h on an inpa-
tient or outpatient basis. Vancomycin levels were monitored on Day 2 (!1)
and Day 6 (+1), with dose adjustments based on a target trough of
15–20 lg/mL.20 Patients received aztreonam for Gram-negative coverage,
which was discontinued once baseline cultures did not reveal Gram-
negative organisms. Both groups were treated for at least 5 days and no
more than 14 days, with the duration of therapy based on the investigators’
assessment of signs and symptoms of ABSSSI.
Study visits took place at screening, daily during treatment, FU (Day 14+1)
and late FU (LFU; Days 21–28). Telephone FU was conducted for all patients
30 days after the last dose of study drug to obtain 28 day all-cause mortality
rates, adverse events (AEs) and use of post-treatment medications.
Efficacy assessments
The FDA-defined primary efficacy endpoint was the objective response at
48–72 h (+2) following treatment initiation and defined as 20% reduction
in erythema of the ABSSSI lesion determined by digital planimetry of the
leading edge without evidence of clinical failure. Clinical failure at this time-
point was defined as any of the following: (i) ,20% reduction in erythema
area determined by digital planimetry; (ii) administration of rescue antibac-
terial drug therapy or non-study antibacterial drug therapy before the pri-
mary efficacy endpoint assessment; (iii) unplanned surgical intervention
except for limited bedside debridement and standard wound care before the
primary efficacy endpoint assessment; or (iv) death within 74 h after treat-
ment initiation. Patients were classified as clinical failures in the ITT analysis if
digital planimetry was not available within the 48–72 h (+2) window.
The EMA-defined primary efficacy measure was the investigator assess-
ment of clinical cure (no remaining signs or symptoms) at the FU visit in the
ITT population. An additional secondary endpoint was investigator-assessed
success (cure or improved and no further antibiotic needed) at the FU visit.
Clinical response at FU and LFU was based on investigator assessment
of ABSSSI signs and symptoms and categorized as cure (complete reso-
lution of symptoms); improved (near resolution with some remaining
symptoms not requiring antibiotic therapy); failure (additional non-study
antibiotics or unplanned major surgical intervention required); or indeter-
minate. Patients lost to FU (or with indeterminate outcomes) and those
categorized as improved were considered failures in the primary analysis.
Other antibiotic studies in skin infections have defined a successful out-
come as resolution or near resolution of signs and symptoms that no longer
require antibiotic therapy. This definition aligns with the definition of suc-
cess in this study.
Because a previous Phase 2 study showed statistically better outcomes
in obese patients, it was pre-specified that data sets would be analysed by
patient baseline BMI for patients with baseline BMI ,30 kg/m2 and patients
with baseline BMI30 kg/m2.17
Patients’ subjective assessment of pain was recorded on a numerical
rating scale ranging from 0 (no pain) to 10 (worst imaginable pain) at
screening, during treatment, end of treatment (EOT), FU and LFU.
Microbiological assessments
Microbiological response for patients in the microbiological ITT (MITT) and
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baseline and post-baseline cultures through the FU and LFU visits, suscepti-
bility testing and the clinical response assigned by the investigator. ABSSSI
samples were collected before initiation of any rescue therapy and from all
clinical failures that had material available for culture. Microbiological re-
sponse was categorized as documented eradicated (baseline pathogen
absent in FU cultures); presumed eradicated (no FU material available for
culture with a clinical response of success); documented persisted (baseline
pathogen present in FU cultures); or presumed persisted (no FU material
available for culture with an investigator-assessed response of failure).
Safety and tolerability assessments
Safety assessments included all AEs, physical examinations, vital signs,
12-lead ECGs at baseline and if clinically indicated thereafter, and clinical la-
boratory tests. AEs were summarized by treatment group and overall for
the safety analysis set. Treatment-emergent AEs (TEAEs) were those that
occurred or worsened in severity after administration of the first dose of the
study drug through the telephone FU with patients 30 days after the last
dose. The Medical Dictionary for Regulatory Activities Version 16.1 was used
to code AEs.
Statistical analysis
Separate statistical analysis plans were prospectively developed prior to
database lock and unblinding for the FDA and the EMA endpoints. All clinical
efficacy outcomes were analysed for the ITT population. The safety analysis
set included all enrolled patients who received1 dose of the study drug.
Analysis of microbiological outcomes was based on the MITT popula-
tion. There were multiple ME and clinically evaluable (CE) analysis sets
based on the timing of assessments [48–72 h (+2), EOT, FU and LFU].
Continuous variables were described with descriptive statistics such as
mean, standard deviation, median, minimum and maximum while counts
and percentages were calculated for categorical data. The rate of the pri-
mary FDA-defined efficacy endpoint was the sample responder rate
defined as [responder/(responder!non-responder)]. The rate of the pri-
mary EMA-defined efficacy endpoint was the sample cure rate defined as
[cure/(cure! failure)].
A two-sided 95% CI was calculated based on differences between dela-
floxacin and vancomycin/aztreonam in responder rates at 48–72 h (+2)
after initiation of treatment (FDA-defined endpoint) and investigator-
assessed response rates (EMA-defined endpoint) using a non-stratified
method proposed by Miettinen and Nurminen.21 Non-inferiority was con-
cluded if the lower limit of this 95% CI was .#10%, with mean differences
between treatments expressed as delafloxacin minus vancomycin/aztreo-
nam. The FDA-defined primary efficacy analysis was performed on the ITT
analysis set while the EMA-defined primary efficacy analysis included the
ITT and CE at FU analysis sets.
The same analysis method was applied to the comparison of microbio-
logical response rates between treatment groups.
All analyses and summaries were produced using SASV
R
software (SAS
Institute, Inc., Cary, NC, USA) Version 9.3 (or higher).
Results
Patient disposition and analysis sets
Six-hundred and sixty patients were randomized to delafloxacin or
vancomycin/aztreonam and comprised the ITT analysis popula-
tion (Figure 1). Among patients enrolled, 547 (82.9%) completed
the study through the LFU visit. The safety analysis set included
650 patients who received study drug. The median duration of
treatment with delafloxacin was 5 and 5.5 days for the vanco-
mycin/aztreonam group. The median duration of aztreonam/az-
treonam placebo use was 2 days for either group.
Patient demographic and clinical characteristics
Baseline characteristics were similar between treatment groups
(Table 1). The majority of patients were men (62.9%) and
Caucasian (91.1%), with a mean (SD) age of 45.8 (+14.2) years
and a mean (SD) BMI of 28.1 (6.4) kg/m2; 32.4% of patients had
BMI 30 kg/m2. Less than 20% of patients received antibacterial
therapy prior to randomization (15.7% in the delafloxacin group
and 21.6% in the vancomycin/aztreonam group).
The types of ABSSSI were similarly distributed across the two
treatment groups (Table 2). Baseline lesion size was similar between
the two treatment groups with a median lesion size 300 cm2.
Of the 660 enrolled patients, 490 (74.2%) had a positive ABSSSI cul-
ture. Of patients with positive cultures, Staphylococcus aureus was
identified in 65.4% of patients treated with delafloxacin and 66.8%
of those in the vancomycin/aztreonam group; MRSA infections were
confirmed in 78 (32.1%) and 91 (36.8%) patients in the delafloxacin
and vancomycin/aztreonam groups, respectively. Delafloxacin
MIC50/90 was 0.008 and 0.25 mg/L (range 0.002–0.5 mg/L) for
S. aureus; 0.12 and 0.25 mg/L (range 0.004–0.5 mg/L) for MRSA
and 0.008 and 0.12 mg/L (range 0.002–0.5 mg/L) for MSSA.
Approximately 40% of S. aureus isolates were levofloxacin non-
susceptible (delafloxacin MIC range 0.004–0.5 mg/L); the majority
were also MRSA. Of the MITT population, 40 (16.5%) in the delaflox-
acin and 43 (17.4%) in the vancomycin/aztreonam treatment




The percentage of responders at the 48–72 h objective response
assessment in the ITT analysis set was similar between the two
groups at 78.2% and 80.9% for delafloxacin and vancomycin/az-
treonam, respectively, and non-inferiority was declared (Figure 2).
Delafloxacin was comparable to vancomycin!aztreonam for the
objective response at 48–72 h whether using the CE, ME or MITT
analysis sets.
The mean percentage change from baseline in erythema was
similar between the treatment groups at each LFU visit (Figure 3).
Investigator assessment of response
Investigator-assessed cure rates and success rates were similar
between study arms at the FU and LFU visits in the ITT population,
meeting the non-inferiority criteria, and were comparable be-
tween the two treatment groups for the CE, MITT or ME analysis
sets. The investigator-assessed response at the FU visit was also
analysed by infection type and was found to be comparable be-
tween the delafloxacin and the vancomycin/aztreonam treatment
groups (Table 3). Among patients with MRSA, the absolute differ-
ence in cure and clinical success at FU was 6.3% and 1.5% higher,
respectively, for the delafloxacin group compared with the vanco-
mycin/aztreonam group (Figure 2). The cure and success rates
were numerically higher in obese patients at FU and LFU and stat-
istically significantly higher cure at LFU for delafloxacin (71.7%)
compared with vancomycin/aztreonam (57.4%). See Figure 2.
The median baseline patient-reported pain score was 8.0 for ei-
ther group. The mean reduction in pain was comparable between
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treatment groups, with a change from baseline to EOT of #5.4
(3.14) for delafloxacin and#5.1 (3.18) for vancomycin/aztreonam.
Microbiological efficacy
In the ME population at FU, microbiological responses were docu-
mented or presumed eradicated in 175 of 179 (97.8%) and 181 of
184 (98.4%) of patients treated with delafloxacin and vancomycin/
aztreonam, respectively. Among patients with MRSA isolated at
baseline, 100% and 98.5% of responses in the delafloxacin and
vancomycin/aztreonam groups, respectively, were documented or
presumed eradicated. Additionally, there was 100% documented
or presumed eradication for the levofloxacin non-susceptible
S. aureus isolates in the delafloxacin group. Per pathogen early ob-
jective response at 48–72 h and microbiological response rates at
FU against pathogens that cause ABSSSI including Gram-positive
pathogens including MRSA and Gram-negative pathogens were
similar between delafloxacin and vancomycin/aztreonam patients
(see Table 4). No superinfections were identified in either treatment
group. New infections were detected in four patients including two
in the delafloxacin group and two in the vancomycin/aztreonam
group.
Safety
Among the safety analysis set (n"650),1 TEAE was observed in
154 patients (47.5%) treated with delafloxacin and 193 patients
(59.2%) in the vancomycin/aztreonam group (Table 5).
The majority of TEAEs were considered mild and unrelated to
study drug in both groups, with a lower percentage of patients
experiencing treatment-related TEAEs in the delafloxacin arm
compared with vancomycin/aztreonam. The most common
treatment-related AEs in delafloxacin-treated patients were
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Lost to FU (n=24) 
Withdrawal of consent (n=15) 
AE (n=3) 
Lack of efficacy (n=3) 
Non-compliance with study drug (n=2) 




Lost to FU (n=29) 
Withdrawal of consent (n=9) 
AE (n=9) 
Lack of efficacy (n=1) 
Non-compliance with study drug (n=2) 
No reason provided (n=1) 
Death (n=1) 
Other (n=6) 
Figure 1. CONSORT diagram of patient disposition. ITT analysis set included all patients who were randomly assigned to treatment. CE analysis set
included all patients in the ITT population who: (i) received 80% of the total expected doses of the assigned study drug or were clinical failures and
received 4 doses of study drug; (ii) did not receive any concomitant, systemic antibacterial therapy with activity against the identified pathogen;
and (iii) had no major protocol deviations. MITT analysis set consisted of all patients in the ITT analysis set that had bacterial pathogens known to
cause ABSSSI at baseline. ME analysis set included all patients in the MITT population who met the criteria established for the CE analysis set. SAF,
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nausea and diarrhoea. Extensive analysis of AEs typically seen
with fluoroquinolones was conducted. There were no cases of
Clostridium difficile diarrhoea and there were no cases of tendinitis
or tendon rupture, peripheral neuropathy or myopathy thought to
be related to delafloxacin treatment. One delafloxacin-treated pa-
tient and two vancomycin/aztreonam-treated patients had a re-
port of hypoglycaemia related to treatment; two delafloxacin
patients and one vancomycin/aztreonam patient had reported
hyperglycaemia potentially related to treatment. Intensive glu-
cose monitoring for 12 h post-dose in patients who were also
undergoing pharmacokinetic testing did not show differences be-
tween the two treatment groups (Figure 4). Treatment-related in-
fusion reactions (extravasations, pain, oedema, phlebitis, swelling,
etc.) occurred in 3% of patients in each treatment group. Renal fail-
ure was reported as potentially related to treatment in three pa-
tients on vancomycin/aztreonam compared with one report of
renal impairment on delafloxacin. The occurrence of TEAEs result-
ing in premature study drug discontinuation was lower in the
delafloxacin group compared with the vancomycin/aztreonam
arm (0.9% and 4.3%, respectively).
The rate of serious AEs was equal between the two treatment
groups (3.7%), respectively. Of those, none in the delafloxacin
treatment group and one in the vancomycin/aztreonam treat-
ment group were considered to be potentially related to treat-
ment. One death occurred in each treatment arm, with neither
considered related to the study drug.
The groups were generally similar regarding changes from
baseline in haematology and serum chemistry. Vital sign
measurements, physical examination findings and ECGs were un-
remarkable. There were no increases in hepatic AEs in the delaflox-
acin treatment group when compared with vancomycin/
aztreonam. In all patients regardless of baseline medical history or
baseline laboratories, only three patients in the delafloxacin treat-
ment group reported ALT .5% upper limit of normal (ULN) result










46.3+13.91 (18–94) 45.3+14.4 (19–90)
Age category (years), n (%)
65 309 (93.4) 309 (93.9)
.65 22 (6.6) 20 (6.1)
.75 7 (2.1) 10 (3.0)
Men, n (%) 206 (62.2) 209 (63.5)
Race, n (%)
white 297 (89.7) 304 (92.4)
black or African American 27 (8.2) 19 (5.8)
American Indian or
Alaska native
5 (1.5) 2 (0.6)
Asian 1 (0.3) 1 (0.3)
native Hawaiian or
other Pacific Islander
1 (0.3) 2 (0.6)
other 0 1 (0.3)
Ethnicity, n (%)
Hispanic or Latino 101 (30.5) 103 (31.3)
Region, n (%)
Europe 63 (19.0) 55 (16.7)
North America 268 (81.0) 274 (83.3)
BMI (kg/m2), mean+ SD 28.4+6.42 27.9+6.36
BMI30 kg/m2, n (%) 120 (36.3) 94 (28.6)
Diabetes, n (%) 30 (9.1) 27 (8.2)
Prior antibiotic use, n (%) 52 (15.7) 71 (21.6)
Baseline pain score, mean+ SD 7.9 (2.0) 7.8 (2.2)
Duration of exposure
n 324 326
mean (SD) days 6.18 (2.81) 6.15 (2.62)
median days 5.00 5.50
min, max days 0.5, 14.0 0.5, 14.0







ABSSSI category, n (%)
cellulitis/erysipelas 128 (38.7) 128 (38.9)
wound infection 116 (35.0) 116 (35.3)
major cutaneous abscess 84 (25.4) 83 (25.2)
burn infection 3 (0.9) 2 (0.6)












Systemic signs, n (%)
lymph node enlargement 285 (86.1) 287 (87.2)
elevated C-reactive
protein, .10% ULN
131 (39.6) 136 (41.3)
elevated white blood
count,10000 cells/lL
159 (48.0) 165 (50.2)
fever,38 C 78 (23.6) 63 (19.1)
lymphangitis 68 (20.5) 55 (16.7)
Bacteraemia, n (%) 6 (1.8) 9 (2.7)
Local signs, n (%)
erythema/extension of redness 329 (99.4) 328 (99.7)
heat/localized warmth 328 (99.1) 326 (99.1)
pain/tenderness 328 (99.1) 327 (99.4)
swelling/induration 323 (97.6) 324 (98.5)
drainage/discharge 209 (63.1) 207 (62.9)
fluctuance 175 (52.9) 179 (54.4)
Pathogens identified at
baseline (MITT), n (%)a
S. aureusb 159 (65.4) 165 (66.8)
MRSA 78 (32.1) 91 (36.8)
MSSA 82 (33.7) 74 (30.0)
aPatients with baseline pathogens: N"243 for delafloxacin and N"247
for vancomycin/aztreonam.
bPatients with both MRSA and MSSA were counted only once.
Percentages based on number of patients with baseline pathogens.
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at any time in the study, compared with five patients in the vanco-
mycin/aztreonam treatment groups. Only two patients in either
treatment group had AST .5% ULN any time during the trial
(see Table S3). There were no reports of cases meeting the Hy’s
law definition in any patients during this study. Serum creatinine
.2% ULN was seen in three vancomycin-treated patients any time
during the trial, compared with no reports in delafloxacin-treated
patients.
Discussion
This large, multicentre, double-blind, randomized, Phase 3 trial es-
tablished that delafloxacin, an anionic fluoroquinolone, was non-
inferior to vancomycin/aztreonam for the treatment of ABSSSIs.
The non-inferiority of delafloxacin and vancomycin/aztreonam
was demonstrated for the objective response at 48–72 h after initi-
ation of treatment (FDA primary endpoint) and the investigator-
assessed cure at FU (EMA primary endpoint). Moreover, across the
various sensitivity analyses and secondary objectives, the delafloxa-
cin and vancomycin/aztreonam arms were comparable. This study
demonstrates that delafloxacin monotherapy is effective across a
range of Gram-positive and -negative pathogens, and was compar-
able to vancomycin in the treatment of MRSA. Treatment with
vancomycin requires a second antibiotic (aztreonam in this study) as
initial empirical therapy if Gram-negative pathogens are suspected.
The focus of recent antibiotic development in ABSSSI has been
on the coverage of Gram-positive infections, particularly MRSA.
However, the risk for inappropriate antimicrobial therapy
ITT population analysis set
Subgroup
Delafloxacin
events/total   (%)





Patient BMI category (ITT)













































































Investigator-assessed cure at FU
Investigator-assessed success at FU
Investigator-assessed cure at LFU
Investigator-assessed success at LFU
Objective response at 48–72 h
Objective response at 48–72 h
MRSA infections - investigator-assessed cure at FU
MRSA infections - investigator-assessed success at FU
MRSA infections - investigator-assessed cure at LFU
MRSA infections - investigator-assessed success at LFU
Objective response - non-obese at 48–72 h
Objective response - obese at 48–72 h
Investigator-assessed cure at FU - non-obese
Investigator-assessed cure at FU - obese
Investigator-assessed success at FU - non-obese
Investigator-assessed success FU - obese
Investigator-assessed cure at LFU - non-obese
Investigator-assessed cure at LFU - obese
Investigator-assessed success at LFU - non-obese
Investigator-assessed success LFU - obese
Investigator-assessed cure at FU
Investigator-assessed success at FU
Investigator-assessed cure at LFU
Investigator-assessed success at LFU
Figure 2. Objective response and investigator-assessed response at FU and LFU by analysis set, MRSA infection at baseline and BMI category.
*Primary endpoint. Cure"no remaining signs and symptoms. Improved" some remaining signs and symptoms, but no further antibiotics required.
Success" cure! improved. ITT, all patients randomized; MITT, ITT patients with eligible pathogen; CE patients who completed activities as defined in
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increases in skin infections when Gram-negative and mixed cul-
tures are present.22,23 Other MDR bacteria are demonstrating
similar trends, as seen with the rise in MRSA, and are increasing in
prevalence in ABSSSIs. In addition, while Gram-negative patho-
gens can play an important role in long-standing polymicrobial
infections, they are also increasingly found in monomicrobial
skin and soft tissue infections (SSTIs).5,6 Gram-negative only cul-
tures have been reported at a rate of 12.8% and mixed cultures in
10.6%–20.5% of patients hospitalized with serious skin
infections.24,25
Initial therapy failure rates in skin infections have been shown
to range from 16% to 43% depending on type of infection and
results in additional days of hospitalization and increased
costs.26,27 Combination therapy is used 40% of the time; however,
the pathogen is never identified in 61% of cases. When choosing
empirical therapy for infections with presumed Gram-negative
bacteria, local epidemiology should be taken into account and
consideration given to individual patient characteristics such as
type of infection including certain SSTIs, comorbidities such as
diabetes and compromised vascular profusion and by setting,
e.g. residence in a nursing home or recent hospitalization.4,21–28
In this study, cure was defined by more stringent criteria, which
required patients to be completely cured, and not merely im-
proved for a positive investigator response. Other antibiotic studies
in skin infections have defined a successful outcome as clinical im-
provement where no further antibiotic therapy is required. This
aligns with the definition of success in this study. Whether using
cure or success (cure! improved), delafloxacin was comparable
to vancomycin/aztreonam in later clinical response at FU and LFU
demonstrating a sustained clinical response.
Delafloxacin was well tolerated with a lower overall discontinu-
ation rate compared with vancomycin/aztreonam. The safety pro-
file reported in this study is consistent with previous clinical
studies.16,17 Previous studies have shown that delafloxacin has
minimal potential for drug interactions and no evidence of QT
interval prolongation or phototoxicity.29–32 Taken together, dela-
floxacin has similar efficacy and safety compared with vanco-
mycin/aztreonam for the treatment of ABSSSI. Delafloxacin offers
the potential for the treatment of infections caused by Gram-
positive pathogens including MRSA and Gram-negative pathogens,
without the need for combination therapy.
Pharmacotherapy of obese patients presents additional chal-
lenges to physicians and pharmacists.33 A previous Phase 2 study
noted better outcomes with delafloxacin in obese patients than
vancomycin at FU and LFU.16 Unlike vancomycin, delafloxacin does
not require weight-based dosing or drug monitoring. The results of
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Figure 3. Percentage change from baseline in reduction of erythema (digital planimetry) at each visit (ITT population).








cure 86/128 (67.2%) 78/128 (60.9%) 6.3 (#5.52, 17.87)
success 107/128 (83.6%) 108/128 (84.4%) #0.8 (#9.94, 8.37)
Abscess
cure 44/84 (52.4%) 40/83 (48.2%) 4.2 (#10.93, 19.12)
success 70/84 (83.3%) 70/83 (84.3%) #1.0 (#12.46, 10.47)
Wound
cure 39/116 (33.6%) 48/116 (41.4%) #7.8 (#20.02, 4.72)
success 90/116 (77.6%) 94/116 (81.0%) #3.5 (#13.97, 7.08)
Burn
cure 3/3 (100%) 0/2 (0.0%) 100.0 (2.02, 100.00)
success 3/3 (100%) 2/2 (100%) not evaluable
Cure" complete resolution of symptoms. Success" cure plus improved
and no further antibiotic needed.
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the investigator-assessed outcome at FU and LFU favoured dela-
floxacin, although it failed to meet statistical significance in all but
investigator-assessed cure at LFU. However, the current study was
not stratified for obesity at enrolment and a weight limit of 140 kg
was instituted due to difficulties in blinding of vancomycin in an
obese population.
Other limitations to this study include a low number of burn in-
fections and surgical wounds and the number of Gram-negative
pathogens was limited by use of the current ABSSSI definition that
favours Gram-positive infections. There were a low number of
older adults and non-whites and the rate of diabetes was lower
than in the general population.
Delafloxacin was found to have comparable clinical activity to
vancomycin in the treatment of patients with ABSSSI by early ob-
jective response, later clinical assessments and microbiological re-
sponse including impact on MRSA. Additionally, delafloxacin was
well tolerated. With both intravenous and oral formulations, dela-
floxacin is appropriate for the treatment of diverse skin infection
types due to Gram-positive and -negative bacteria, including pa-
tients with MRSA.
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